Belite Bio, Inc (BLTE) stock
BLTENasdaqPharmaceutical PreparationsFiscal year ends December 31
$157.72−4.84 (-2.98%)
Close on Nov 17, 2026Market cap $6.20BP/E –Yield –
Belite Bio operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
For fiscal 2025 it was -$84.21M. The highest annual figure on record is -$5.74M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$84.21M | – |
| FY2024 | Dec 31, 2024 | -$40.00M | – |
| FY2023 | Dec 31, 2023 | -$31.67M | – |
| FY2022 | Dec 31, 2022 | -$12.82M | – |
| FY2021 | Dec 31, 2021 | -$9.80M | – |
| FY2020 | Dec 31, 2020 | -$5.74M | – |
See a number that looks wrong?